comparemela.com
Home
Live Updates
NEC Corporation: Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023 : comparemela.com
NEC Corporation: Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023
- New immunological data assessed by tetramer staining confirms the induction of T cell responses in treated patients- All trial patients treated with TG4050 monotherapy continue to remain in remission
Related Keywords
Chicago ,
Illinois ,
United States ,
Zeiten ,
Mecklenburg Vorpommern ,
Germany ,
Tokyo ,
Japan ,
Ankara ,
Turkey ,
United Kingdom ,
France ,
American ,
Christophe Le Tourneau ,
Masamitsu Kitase ,
Christian Ottensmeier ,
Le Tourneau ,
Alexandra Martinez ,
Stefan Klotter ,
Jean Pierre Delord ,
Alessandro Riva ,
Yujie Zhao ,
Transgene Euronext ,
Institut Curie ,
Life Science Division ,
University Of Liverpool ,
Linkedin ,
American Society Of Clinical Oncology ,
Clatterbridge Cancer Centre ,
Head Of The Department Drug Development ,
Head Of Surgical Department ,
Nec Ai Drug Development Business ,
Twitter ,
Euronext Paris ,
American Society ,
Clinical Oncology ,
Annual Meeting ,
Corporate Senior ,
Serious Adverse Events ,
Consultant Medical Oncologist ,
Drug Development ,
Consultant Medical Oncology ,
Consultant Immunology ,
Associate Professor ,
Mayo Clinic ,
Associate Head ,
Surgical Department ,
Vaccinia Ankara ,
Artificial Intelligence ,
Development Business ,
Risk Factors ,
Universal Registration Document ,
Stabile Ertr ,
Chart Profi Stefan Klotter ,
Blue Chips ,
Corporation ,
Transgene ,
Present ,
Data ,
G4050 ,
Individualized ,
Dancer ,
Vaccine ,
Showing ,
Induces ,
Specific ,
Immune ,
Responses ,
Against ,
Head ,
Neck ,
Arcinoma ,
Disco ,
023 ,
comparemela.com © 2020. All Rights Reserved.